Cargando…
Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy
Estrogen receptor (ER) testing of breast cancer imperfectly predicts response to endocrine therapy (ET). We hypothesize that a brief estradiol challenge will increase tumor progesterone receptor (PgR) levels only in tumors with functional ER. In this prospective, phase 2, single-center, single-arm t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854611/ https://www.ncbi.nlm.nih.gov/pubmed/33531464 http://dx.doi.org/10.1038/s41467-020-20814-9 |
_version_ | 1783646116384866304 |
---|---|
author | Dehdashti, Farrokh Wu, Ningying Ma, Cynthia X. Naughton, Michael J. Katzenellenbogen, John A. Siegel, Barry A. |
author_facet | Dehdashti, Farrokh Wu, Ningying Ma, Cynthia X. Naughton, Michael J. Katzenellenbogen, John A. Siegel, Barry A. |
author_sort | Dehdashti, Farrokh |
collection | PubMed |
description | Estrogen receptor (ER) testing of breast cancer imperfectly predicts response to endocrine therapy (ET). We hypothesize that a brief estradiol challenge will increase tumor progesterone receptor (PgR) levels only in tumors with functional ER. In this prospective, phase 2, single-center, single-arm trial (NCT02455453), we report the association of response to ET with change in tumor uptake of the progestin analog, 21-[(18)F]fluorofuranylnorprogesterone (FFNP), before and after a one-day estradiol challenge. In 43 postmenopausal women with advanced ER+ breast cancer, we show a post-challenge increase in tumor FFNP uptake only in 28 subjects with clinical benefit from ET (responders), but not in 15 without clinical benefit (nonresponders) (p < 0.0001), indicating 100% sensitivity and specificity. We further show significantly longer survival (p < 0.0001) in the responding subjects. Our results demonstrate that change in tumor FFNP uptake after estradiol challenge is highly predictive of response to ET in women with ER+ breast cancer. |
format | Online Article Text |
id | pubmed-7854611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78546112021-02-11 Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy Dehdashti, Farrokh Wu, Ningying Ma, Cynthia X. Naughton, Michael J. Katzenellenbogen, John A. Siegel, Barry A. Nat Commun Article Estrogen receptor (ER) testing of breast cancer imperfectly predicts response to endocrine therapy (ET). We hypothesize that a brief estradiol challenge will increase tumor progesterone receptor (PgR) levels only in tumors with functional ER. In this prospective, phase 2, single-center, single-arm trial (NCT02455453), we report the association of response to ET with change in tumor uptake of the progestin analog, 21-[(18)F]fluorofuranylnorprogesterone (FFNP), before and after a one-day estradiol challenge. In 43 postmenopausal women with advanced ER+ breast cancer, we show a post-challenge increase in tumor FFNP uptake only in 28 subjects with clinical benefit from ET (responders), but not in 15 without clinical benefit (nonresponders) (p < 0.0001), indicating 100% sensitivity and specificity. We further show significantly longer survival (p < 0.0001) in the responding subjects. Our results demonstrate that change in tumor FFNP uptake after estradiol challenge is highly predictive of response to ET in women with ER+ breast cancer. Nature Publishing Group UK 2021-02-02 /pmc/articles/PMC7854611/ /pubmed/33531464 http://dx.doi.org/10.1038/s41467-020-20814-9 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Dehdashti, Farrokh Wu, Ningying Ma, Cynthia X. Naughton, Michael J. Katzenellenbogen, John A. Siegel, Barry A. Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
title | Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
title_full | Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
title_fullStr | Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
title_full_unstemmed | Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
title_short | Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
title_sort | association of pet-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854611/ https://www.ncbi.nlm.nih.gov/pubmed/33531464 http://dx.doi.org/10.1038/s41467-020-20814-9 |
work_keys_str_mv | AT dehdashtifarrokh associationofpetbasedestradiolchallengetestforbreastcancerprogesteronereceptorswithresponsetoendocrinetherapy AT wuningying associationofpetbasedestradiolchallengetestforbreastcancerprogesteronereceptorswithresponsetoendocrinetherapy AT macynthiax associationofpetbasedestradiolchallengetestforbreastcancerprogesteronereceptorswithresponsetoendocrinetherapy AT naughtonmichaelj associationofpetbasedestradiolchallengetestforbreastcancerprogesteronereceptorswithresponsetoendocrinetherapy AT katzenellenbogenjohna associationofpetbasedestradiolchallengetestforbreastcancerprogesteronereceptorswithresponsetoendocrinetherapy AT siegelbarrya associationofpetbasedestradiolchallengetestforbreastcancerprogesteronereceptorswithresponsetoendocrinetherapy |